Dysregulation of the endocannabinoid system is known to interfere with emotional processing of stressful events. Here, we studied the role of cannabinoid receptor type 1 (CB1) signaling in stress-coping behaviors using the forced swim test (FST) with repeated exposures. We compared effects of genetic inactivation with pharmacological blockade of CB1 receptors both in male and female mice. In addition, we investigated potential interactions of the endocannabinoid system with monoaminergic and neurotrophin systems of the brain. Naive CB1 receptor-deficient mice (CB1
Introduction
Endocannabinoids are fatty acid derivatives that are synthesized and released on demand from postsynaptic terminals. 1 They bind to presynaptically localized cannabinoid type 1 (CB1) receptors where they constrain the activity of various neurotransmitter systems, including glutamate, 2 GABA, 3 acetylcholine, 4 noradrenaline (NA) 5 and serotonin (5-HT). 5, 6 The endocannabinoid system has, thus, been recognized as one of the major neuromodulatory systems of the brain that functions to maintain the homeostasis of various states including mood and emotion. 1, 7 Preclinical research in rodents during the last decade has helped to elucidate the role of the endocannabinoid system in fear and anxiety. For instance, the importance of endocannabinoid signaling for the extinction of aversive memories was recently demonstrated in our laboratory.
Endocannabinoid signaling seems to be indispensable for the adequate coping of the organism with aversive and stressful situations. These findings fit well with the observations that pharmacologically increased endocannabinoid signaling exerts anxiolytic effects in rodents 10, 11 and, thus, could represent an important lead for the development of new anti-anxiety drugs. 10, 12, 13 In agreement with these findings, pharmacological blockade or genetic inactivation of CB1 receptors led to anxiogenic responses. 11, [14] [15] [16] Nevertheless, there are some studies, which have failed to show an effect on anxiety measures 8 or even demonstrated anxiolytic effects. 17 These discrepancies might be ascribed to differences in the genetic background of the rodent 8, 15, 16 or in the test conditions, 18 especially regarding the averseness of the test situation. 19 Given the high comorbidity between anxiety and major depression, 20 recent research has also focused on a potential role of the endocannabinoid system in the pathology of major depression 13, 21 particularly of the melancholic subtype. 13 CB1 receptor-deficient mice share several symptoms with patients suffering from melancholic depression such as, for example, altered responsiveness to reward stimuli, 22 altered neurovegetative functions, 23 a predominance and persistence of aversive memories, 8, 9 and possibly neurodegeneration. 24 Furthermore, it was shown by us and others that impaired endocannabinoid signaling can lead to sustained hyperreactivity of the hypothalamic-pituitaryadrenocortical (HPA) axis 23, 25 and might also interfere with the proliferation of neural progenitor cells. 26 Human postmortem studies of depressed suicide victims, which have revealed dysregulations of the endocannabinoid system in the prefrontal cortex 27, 28 further strengthen the notion of a potential role of the endocannabinoid system in depression. In this context, it is also worthwhile to note that the most frequently encountered side effects during the recently conducted phase-III trials of the CB1 receptor antagonist rimonabant (SR141716) as an anti-obesity treatment included anxiety and mood disturbances. [29] [30] [31] Studies on the function of endocannabinoids in classic animal models of depression or antidepressant-like behavior, however, have so far been sparse and revealed contradictory results in rats and mice. The forced swim test (FST) represents one of the most widely used tests to detect antidepressant-like activities of drugs as well as depressionlike behavior in genetically engineered mice. 32 Drugs, which elevate the endocannabinoid tone such as the fatty acid amide hydrolase inhibitor URB597 or the endocannabinoid re-uptake inhibitor AM404, were demonstrated to exert antidepressant-like effects 6, 33 in the FST in terms of reduced immobility. Surprisingly, however, also CB1 receptor antagonists such as SR141716 given in a higher dose range (3-10 mg/kg) were able to produce similar antidepressantlike effects in this test. 5, 17 CB1 receptor-deficient mice on a different genetic background (CD1) than our mice (C57BL/6N) have failed so far to show any behavioural alterations in the FST. 34 Consequently, the issue of whether or not the blockade of endocannabinoid signaling could actually be of advantage or disadvantage for the potential treatment of depression is from the preclinical view still under debate. 13, 21 Given the higher prevalence of females to develop depression, 35 systematic investigations of the interaction between sex and endocannabinoid signaling in animal models of depression are still missing. In addition, little is known about the neural substrates underlying the potential antidepressant-like effects of drugs interfering with endocannabinoid signaling. 5, 6 In the present study, we investigated the effects of impaired CB1 receptor signaling on stress-coping behaviors in both males and females using the FST with repeated exposures. Effects of the genetic inactivation of CB1 receptors were compared to effects of the pharmacological blockade by the selective CB1 receptor antagonist SR141716. Potential links between the endocannabinoid system and monoaminergic systems of the brain were assessed by analyzing (i) sensitivity to different classes of antidepressants in the FST, (ii) basal monoamine oxidase (MAO) A and B activities, and (iii) hippocampus tissue content of catecholamines and 5-HT after FST in CB1 receptor-deficient mice (CB1
À/À
) and wild-type littermates (CB1 þ / þ ). Furthermore, mRNA levels of the vesicular glutamate transporter type 1 (VGLUT1), a marker of antidepressant activity, 36 were evaluated, as well as mRNA levels of brain-derived neurotrophic factor (BDNF), a neurotrophic factor strongly implicated in depression as well as in the behavioral response to forced swimming. 37 
Results
Genetic deletion of CB1 receptors increases passive-coping behavior in the FST CB1 þ / þ and CB1 À/À mice of both sexes were subjected to forced swimming in three consecutive sessions on days 1, 2 and 21 ( Figure 1 ) in order to study the persistence of alterations in behavioral stress-coping strategies over repeated testing.
With respect to long-term changes in struggling from day 1 to 21, animals showed decreased struggling on days 2 and 21 as compared to the first exposure on day 1 (day: F 2,140 ¼ 71.4, Po0.001; three-way ANOVA (genotype, sex, day) for repeated measures (day); Figures 1a and d) , independent of genotype and sex. Moreover, there was a significant genotype Â day interaction (F 2,140 ¼ 6.0, P ¼ 0.003), reflecting decreased struggling of CB1 À/À mice of both sexes on day 1 and increased struggling of male CB1 À/À mice on days 2 and 21 as compared to their CB1
littermates. Male mice of both genotypes generally struggled more than their female littermates (sex:
With respect to long-term changes in floating from day 1 to 21, animals showed increased floating on days 2 and 21 as compared to the first exposure on day 1 (day: F 2,140 ¼ 52.8, Po0.001; three-way ANOVA (genotype, sex, day) for repeated measures (day); Figures 1b and e), independent of genotype and sex. Moreover, there was a significant genotype Â day interaction (F 2,140 ¼ 4.1, P ¼ 0.018), reflecting increased floating of CB1 À/À mice of both sexes on day 1. Integration of the behavioral performance over the entire 6-min observation period may cause information loss about the development of behavioral stress coping over the course of the stressor exposure. Therefore, we additionally analyzed the data in 1-min intervals in order to assess short-term (i.e., within-session) changes in floating (Figures 1c and f) . In general, there were significant genotype Â interval interactions for each of the testing days (F 5,355 43.2, Po0.008; three-way ANOVAs (genotype, sex, interval) for repeated measures (interval)), independent of the sex, reflecting the fact that CB1 À/À animals showed a more pronounced increase in floating than their CB1 þ / þ littermates with ongoing stressor exposure. The higher susceptibility of CB1 À/À mice to acquire passive stress-coping strategies was substantiated by a significant genotype effect for day 1 (F 1,71 ¼ 10.7, P ¼ 0.001). Although females and males differed in the course of floating on days 2 and 21 (sexinterval: F 5,355 44.2, Po0.001), the effects of CB1 deletion on the development of floating were similar for both males and females (genotype Â sex Â interval: F 5,355 o1.9, P40.089). Nevertheless, we additionally analyzed floating behavior separately per sex. On day 1, male CB1 À/À mice showed a significantly higher increase in floating over the course of the 6-min exposure than their CB1 þ / þ littermates (genotype: F 1,37 ¼ 5.7, P ¼ 0.022, genotype Â interval: Figure 1f ). It has to be noted that, independent of sex, CB1 þ / þ but not CB1
À/À mice usually spent more time floating during the first minute of the following FST exposure than during the last minute of the previous FST exposure.
Pharmacological blockade of CB1 receptors alters coping behavior in the FST To assess whether the pharmacological blockade of CB1 receptors leads to similar behavioral responses in the FST as the genetic inactivation, we applied the selective CB1 receptor antagonist SR141716 to male and female C57BL/ 6N mice. To mimic the situation in CB1 À/À mice, where the receptor is permanently lost, animals were injected before the FST on day 1, once again approximately 10-12 h later and finally before the FST on day 2 (cf. Wei et al. 38 ). To minimize acute stress responses due to the injection procedure, animals were injected 2 h before the FST.
Struggling was differently affected by pharmacological blockade than by genetic inactivation, because SR141716 (Figures 2b and e) . Nevertheless, independent of sex, antagonist treatment altered the development of total floating time from day 1 to 2 (treatment Â day: F 1,44 ¼ 12.4, P ¼ 0.001; three-way ANOVA (treatment, sex, day) for repeated measures (day); Figures 2b and e) reflecting the fact that SR141716-treated mice did not show a further increase of floating on day 2 as compared to day 1.
Analysis of the within-session development of floating on day 1 (Figures 2c and f) revealed that acute pharmacological blockade by SR141716 led to essentially the same phenotype as observed previously in mice with genetic deletion of CB1 receptors. There was a slight, but not significant, effect of treatment on day 1 (F 1,44 ¼ 3.4, P ¼ 0.073; three-way ANOVA (treatment Â sex Â interval) for repeated measures (interval)), a significant treatment Â interval interaction (F 5,220 ¼ 6.9, Po0.001) but no significant treatment Â sex Â interval interaction (Figures 2c and f) . The floating response following treatment with SR141716 was more pronounced than in vehicle-treated controls, especially towards the end of the stressor exposure, similar to CB1 À/À mice. These conclusions could be confirmed in subsequent separate statistical analyses for both male (treatment Â interval: F 5,110 ¼ 4.7, Po0.001; two-way ANOVA (treatment, interval) for repeated measures (interval); Figure 2c ) and female mice (treatment Â interval: Figure 2f ) on day 1. On day 2, floating was less pronounced following antagonist treatment, especially during the first minutes of the stressor exposure, in both male (treatment Â interval: F 5,110 ¼ 2.4, P ¼ 0.042; two-way ANOVA (treatment, interval) for repeated measures (interval); Figure 2c ) and female mice (treatment Â interval: Figure 2f ). This effect on day 2 was different to the situation in CB1
À/À mice. Apart from these discrepancies, another striking similarity between SR141716-treated animals and CB1 À/À mice was the fact that, independent of sex, vehicle-treated, but not SR141716-treated, animals spent more time floating during the first minute of the FST on day 2 than during the last minute of the FST on day 1.
Effects of SR141716 on FST behavior are specific for CB1 receptors
The partial discrepancies observed between genetic inactivation and pharmacological blockade of CB1 could either be due to potential developmental changes because of the lifelong absence of the receptor in CB1 knockout mice, or due to influences of different environmental factors (animal housing, injection stress) between C57BL/6N mice (shipped from a commercial supplier) and CB1
þ / þ and CB1 À/À mice (housed in our own animal facility). Therefore, we repeated the antagonist experiment with a new batch of naive female CB1 þ / þ and CB1 À/À mice ( Figure 3 ). In contrast to the situation in C57BL/6N mice, SR141716 failed to significantly affect struggling behavior of either CB1 þ / þ or CB1 À/À mice (treatment: F 1,11 o3.5, P40.09; two-way ANOVA (treatment, day) for repeated measures (day)). Furthermore, also in contrast to the situation in C57BL/6N mice, SR141716 treatment of CB1 þ / þ mice did not result in reduced floating on day 2 as indicated by a nonsignificant treatment Â day interaction (F 1,12 ¼ 0.1, P ¼ 0.73; two-way ANOVA (treatment, day) for repeated measures (day)). Instead, SR141716 treatment of CB1
resulted in similar increases of total floating behavior on both days similar to the situation in untreated CB1
À/À mice. Analyzing within-session floating behavior revealed a more pronounced floating response in SR141716-treated CB1 þ / þ mice as compared to vehicle-treated CB1 þ / þ mice on both day 1 (treatment Â interval: F 5,60 ¼ 4.6, P ¼ 0.001; two-way ANOVA (treatment, interval) for repeated measures (interval); Figure 3c ) and day 2 (treatment Â interval:
À/À mice, in contrast, SR141716 failed to affect floating on either day (treatment Â interval: Figure 3f ). Accordingly, three-way ANOVA (genotype, treatment, interval) for repeated measures (interval) revealed significant interactions among all the three factors both on day 1 (F 5,115 ¼ 2.7, P ¼ 0.026) and on day 2 (F 5,115 ¼ 3.7, P ¼ 0.003). This confirmed our observation that CB1
À/À mice develop a more pronounced floating response than CB1
þ / þ mice and demonstrated that SR141716 mediates its effects on behavioral stress coping in a highly specific manner via the CB1 receptor. Unlike the situation in C57BL/6N mice, SR141716 treatment of CB1
wild-type mice revealed essentially the same phenotype as observed previously in untreated CB1
À/À mice on all testing days (cf. Figures 1d-f) .
Sensitivity of FST behavior to desipramine treatment is slightly altered in CB1
À/À mice The effects of anxiolytic drugs have been shown to be impaired in CB1
À/À mice, 39 and only little is known about the interaction of the endocannabinoid system with antidepressants. 40 To examine if the genetic knockout of CB1 leads to a different reaction or sensitivity to antidepressants in the FST, female CB1
þ / þ and CB1 À/À mice were treated with the NA reuptake inhibitor desipramine (Figure 4) .
Desipramine treatment failed to reveal a statistically significant effect on struggling in either genotype (treatment: However, desipramine treatment significantly reduced floating of both CB1 þ / þ and CB1 À/À mice (treatment: F 1,28 ¼ 10.9, P ¼ 0.003; three-way ANOVA (treatment, day, genotype) for repeated measures (day) Figures 4b and e), in particular on day 2 (day Â treatment:
Analyzing within-session floating behavior on both days revealed that desipramine treatment did not affect floating of CB1 þ / þ mice on day 1 (statistics not shown), but led to a significant decrease of floating on day 2 as compared to vehicle-treated CB1 þ / þ mice (treatment: F 1,12 ¼ 5.9, P ¼ 0.032, interval Â treatment: F 5,60 ¼ 2.5, P ¼ 0.044; twoway ANOVA (treatment, interval) for repeated measures (interval); Figure 4c ). CB1 À/À mice showed a slightly higher sensitivity to desipramine treatment than their CB1 þ / þ littermates. They reacted with a decrease of floating as compared to vehicle-treated controls both on day 1 (interval Â treatment: F 5,80 ¼ 2.4, P ¼ 0.045) and on day 2 (treatment: F 1,15 ¼ 9.8, P ¼ 0.007; Figure 4f ). Treatment affected both CB1
þ / þ and CB1 À/À mice in a similar way on day 2 as illustrated by a nonsignificant genotype Â interval Â treatment effect (F 5,140 ¼ 1.4, P ¼ 0.219; three-way ANOVA (genotype Â interval Â treatment) for repeated measures (interval)).
Sensitivity of FST behavior to paroxetine treatment is slightly altered in CB1
À/À mice Treatment with the selective 5-HT reuptake inhibitor paroxetine significantly increased struggling of female
CB1
þ / þ mice (treatment: F 1,14 ¼ 8.6, P ¼ 0.011; two-way ANOVA (treatment, day) for repeated measures (day); Figure  5a ). Treatment affected female CB1 À/À mice in a similar way (F 1,12 ¼ 4.2, P ¼ 0.062; Figure 5d ), but this effect did not reach statistical significance.
Paroxetine treatment significantly reduced total floating time of CB1 þ / þ mice (treatment: F 1,14 ¼ 15.6, P ¼ 0.001; two-way ANOVA (treatment, day) for repeated measures (day); Figure 5b), whereas it had no significant effect on total floating time of CB1 À/À mice (treatment:
Analysis of within-session floating behavior revealed that paroxetine treatment significantly attenuated the increase of floating in CB1 þ / þ mice over the time course of the stressor exposure on day 1 (treatment: F 1,14 ¼ 8.2, P ¼ 0.012; two-way ANOVA (treatment, interval) for repeated measures (interval); Figure 5c ). In contrary, in CB1 À/À mice, paroxetine treatment reduced the increase of floating behavior on day 1 only during the first half of the stressor exposure, while it resulted in increased floating during the second half as compared to untreated controls (interval Â treatment: F 5,60 ¼ 9.5, Po0.001; Figure 5f ). This discrepancy in the development of the floating response to paroxetine between treated CB1
þ / þ and CB1 À/À mice was further substantiated by a significant interval Â treatment Â genotype interaction (F 5,130 ¼ 6.8, Po0.001; three-way ANOVA (genotype Â treatment Â interval) for repeated measures (interval)). On þ / þ mice (treatment: F 1,14 ¼ 13.7, P ¼ 0.002; two-way ANOVA (treatment, interval) for repeated measures (interval); Figure 5c ), whereas this effect failed to reach statistical significance in CB1 À/À mice (treatment: F 1,12 ¼ 3.7, P ¼ 0.078; Figure 5f ).
Basal brain MAO-A and -B enzymatic activity is not altered in CB1
À/À mice Behavior in the FST is known to be strongly affected by monoamine neurotransmission in the brain, 41 and the endocannabinoid system has been suggested to influence monoaminergic transmission. 5, 6 Therefore, we assessed potential dysregulations of monoaminergic metabolism under basal conditions in female CB1 À/À mice by measuring the enzymatic activity of two major enzymes involved in the catabolism of catecholamines and 5-HT, MAO-A and MAO-B. 42 However, no significant genotype differences could be observed in any of the brain regions analyzed, namely cortex, striatum, hippocampus and the rest of the brain (Table 1 ; statistics not shown).
Hippocampal monoamine levels after FST are not significantly affected by the genetic deletion or by the pharmacological blockade of CB1 receptors To further address the hypothesis that the observed phenotype of CB1 À/À mice in the FST might be due to dysregulations of brain monoaminergic systems during activation, we measured hippocampus tissue contents of NA, 5-HT, dopamine (DA) and of their metabolites homovanillic acid (HVA), 3,4-dihydrophenylacetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA) of subchronically SR141716 and vehicle-treated female CB1 À/À and CB1 þ / þ mice, killed 10 min after onset of the second FST exposure on day 2 (cf. Figure 3) . Two-way ANOVA (genotype, treatment) revealed neither any significant genotype or treatment effects, nor any significant genotype Â treatment interaction (Table 2 ; statistics not shown).
Genetic deletion of CB1 receptors does not alter basal VGLUT1 mRNA expression levels Recently, the expression level of VGLUT1 has been demonstrated to act as a potential marker for the activity of antidepressants after chronic treatment. 36 Furthermore, VGLUT1 has been shown to be co-expressed with CB1 receptors in glutamatergic neurons of the cortex and hippocampus. 3 Therefore, we evaluated male CB1
and CB1 À/À mice for their VGLUT1 mRNA expression levels under basal conditions in order to assess if a downregulation of VGLUT1 coincides with the depressionlike FST phenotype in CB1 À/À mice. However, no significant genotype differences in VGLUT1 mRNA expression could be detected in the cortex or any sub-field of the dorsal or ventral hippocampus ( Figure 6 ; statistics not shown).
Genetic deletion of CB1 receptors causes a downregulation of basal BDNF mRNA levels in the CA3 sub-region of the hippocampus Downregulations of BDNF in the hippocampus have been associated with depression-like behavior in the FST, 37 and we have shown that CB1 receptor signaling influences BDNF expression.
2,43 Therefore, we evaluated male CB1
and CB1 À/À mice for their BDNF mRNA expression in the hippocampus under basal conditions. Quantification of in situ hybridization signals revealed no genotype differences in the CA1 and dentate gyrus sub-fields of the hippocampus, but decreased levels of BDNF mRNA in the CA3 region of the hippocampus in CB1 À/À mice as compared to their CB1 þ / þ littermates. This downregulation was apparent, but not statistically significant in the dorsal hippocampus (t 8 ¼ 2.0, P ¼ 0.079; Student's t-test; Figure 7a ), and reached statistical significance in the ventral hippocampus (t 8 ¼ 2.5, P ¼ 0.037; Student's t-test; Figures 7b and c) .
Discussion
We combined genetic inactivation with pharmacological blockade of CB1 receptors to elucidate the role of the endocannabinoid system in stress-coping behaviors using the FST as an animal model, which is sensitive to antidepressant-like activity. The major results can be summarized as follows: (1) Impaired CB1 receptor signaling, by genetic or pharmacological means, led to increased passive stress-coping behavior in the FST in both male and female mice. Criteria for the validity of animal models of neurological disorders usually include face validity, etiological validity (sometimes referred to as an aspect of construct validity), construct validity and predictive validity, whereas various researchers advocate the primacy to one of these criteria. The FST owes much of its popularity to its high predictive validity, as it had originally been devised as a screen for antidepressant-like activities of drugs. 44, 45 Furthermore, in the original interpretation of floating as 'behavioral despair', the test has certain face validity as it could mimic psychomotor impairments, including a 'lack of expenditure of effort', often associated with depression in humans. 44, 46 To evaluate the construct validity of an animal model, such as the FST, is certainly quite a difficult task; especially in light of a malady such as depression, which is such a complex multi-factorial and heterogeneous disease. Furthermore, the fact that almost all animal models of depression rely on certain types of stressors complicates the matter, as stress might be only one of various risk factors to develop depression. Therefore, we would like to emphasize that we used the FST model in the present study in order to detect alterations of passive and active stress-coping behaviors in mice, which might, according to the literature 13,44 mimic a certain endo-phenotype of depressive disorders.
In a highly reproducible manner, CB1 À/À mice demonstrated increased passive coping behavior in the FST, illustrated by decreased struggling and increased floating as compared to CB1 þ / þ mice (Figures 1, 3-5 ). This phenotype was most prominent during the first exposure (day 1; Figure 1 ) and vanished towards the third exposure (day 21), likely because of interplay between stress-coping and long-term memory. 47 These findings of increased floating, especially on day 1, were substantiated by the pharmacological blockade of CB1 receptors in C57BL/6N mice ( Figure 2 ) and in CB1 þ / þ mice ( Figure 3) . Thus, our behavioral data imply that the blockade of CB1 receptors in mice leads to depressive-like symptoms in the FST.
We have recently shown that the CB1 receptor knockout strain generated by us shows no alterations of locomotor activity, 8 a result, which has several times been consistently repeated in our laboratory. Furthermore, SR141716 administration in mice at the dose used by us was repeatedly shown not to affect locomotor activity. 5, 11 Only if applied in extremely high doses, SR141716 has been, in very rare cases, demonstrated to even increase locomotor activity (for review see Wotjak 7 ). Altogether, these findings argue against locomotor effects being responsible for the increased immobility in the FST observed by us.
Our findings are in agreement with other studies in rats and mice, which have demonstrated antidepressant-like effects in the FST (i.e., reduced floating) by cannabinoid signaling enhancing drugs, such as URB597 or AM404. 6, 33 Nevertheless, these studies and others have failed so far to demonstrate any behavioral effects of either pharmacological 6, 33 or genetic 34 blockade of CB1 receptors in the FST.
6,33 Jardinaud et al., 34 for instance, did not observe any genotype difference between CB1 receptor wild-type and deficient mice. 34 In contrast to our study, FST experiments were carried out under bright light by using a smaller cylinder and slightly colder water temperature. Such experimental parameters are known to influence swimming behavior. 48 Furthermore, genetic background belongs to the most important parameters in the FST, 46 and, thus, could also account for the lack of phenotype, as the knockout mice were on a different genetic background than the mice used in the present study (CD1 vs C57BL/6N). The behavioral ineffectiveness of CB1 receptor antagonists described in the other two studies might be due to the relatively low doses used (1 mg/kg of SR141716; 6 1 and 5 mg/kg of AM251 33 ). Nevertheless, there are also reports which even showed decreased floating (i.e., antidepressant-like effects) in response to SR141716 treatment in rats (3 and 10 mg/kg) 17 and NIH Swiss mice (3 mg/kg). 5 These discrepancies demonstrate the complexity of the endocannabinoid system. It seems that the effects of endocannabinoid signaling can vary significantly depending on genetic, experimental and environmental conditions. Accordingly, we also observed slightly different effects of SR141716 on struggling and floating behavior in C57BL/6N animals, which were shipped from a commercial supplier, as compared to CB1 þ / þ mice, which had been backcrossed for more than six generations to C57BL/6N, but were maintained in our own animal facility (Figures 2 and 3) . Furthermore, the efficiency of blocking endocannabinoid signaling, determined by the dose of antagonist used, might influence the behavioral outcome. In this context, it is worthwhile to note that SR141716 in the relatively high dose used by us (10 mg/kg) did not show any effect in CB1 À/À mice, which excluded potential unspecific effects of the drug in the FST. Moreover, this finding precludes a contribution of potential SR141716 sensitive non-CB1 cannabinoid receptors. 15 Regarding the fact that women are known to be more susceptible to develop depression than men, 35 we also compared male and female mice concerning their stress-coping abilities in the FST. Male and female mice generally showed very similar behavioral reactions to repeated FST exposure. Furthermore, also the genetic inactivation and pharmacological blockade of CB1 receptors had similar effects on coping behavior in the FST in both sexes. This suggests that sex differences in mice appeared to be of minor biological significance in this paradigm (Figures 1 and 2) .
The FST is highly sensitive to elevations in monoaminergic neurotransmission as exerted by current antidepressants. 41 In this context, it is of interest that the endocannabinoid system has recently been suggested to modulate monoaminergic transmission. 5, 6 Enhancing anandamide signaling via administration of URB597 was shown to increase spontaneous firing of serotonergic and noradrenergic neurons in the midbrain of rats, accompanied by increased 5-HT outflow in the hippocampus. 6 This effect was blocked by 1 mg/kg SR141716. Surprisingly, however, treating rats with higher doses of the antagonist (3 and 10 mg/kg) was also shown to dose dependently increase 5-HT and NA efflux in various brain regions. 5 Thus, in order to investigate this potential link between endocannabinoid and monoaminergic systems, we undertook two pharmacological experiments assessing the behavioral response of CB1 þ / þ and CB1 À/À mice to two different classes of antidepressants in the FST. Interestingly, CB1
À/À mice reacted more sensitively than their wild-type littermates to desipramine (Figure 4) , a NA reuptake inhibitor, but less sensitively to paroxetine ( Figure 5 ), a selective 5-HT reuptake inhibitor. Detailed analysis of within-session floating behavior of CB1 À/À mice on day 1, furthermore, revealed a significant genotype Â treatment interaction for paroxetine over the time course of the 6 min FST exposure (Figure 5f ). This suggested a time-dependent biphasic influence of endocannabinoid signaling on the behavioral effects exerted by the blockade of 5-HT transporters during FST on day 1. Thus, the blockade of endocannabinoid signaling seems to interfere to some extent with the actions of different kinds of antidepressants, although CB1 receptors, in general, seem to be dispensable for the acute behavioral effects of these antidepressants. Very recently, another study with a similar rationale as ours explored the interaction between SR141716 and fluoxetine or desipramine, respectively, in the FST using female Sabra mice. 40 Yet, Gobshtis et al. could neither demonstrate an interaction between SR141716 and the antidepressant drugs, nor an effect of SR141716 (5 mg/kg) alone. Future studies have to elucidate whether the independence of antidepressant actions from endocannabinoid signaling also holds true for male mice and other kinds or different doses of antidepressants.
Our behavioral results concerning the partly different behavioral effects of antidepressants in CB1 À/À mice prompted us to explore the function of monoaminergic systems in CB1 À/À mice further. Dysregulations of monoaminergic transmission could become manifest in altered enzymatic activity of major catabolic enzymes for monoamines, such as MAO-A and -B. 42 However, we found no evidence for a differential activity of MAO-A or MAO-B in various brain regions of CB1 À/À mice under basal conditions (Table 1) . Still, it is conceivable that altered monoaminergic transmission could only become apparent after strong neuronal activation and, thus, might not necessarily result in up-or downregulation of degrading enzymes such as MAO. Therefore, we also assessed monoamine contents and their metabolites in hippocampi of vehicle-and SR141716-treated CB1 þ / þ and CB1 À/À mice in an activated state, after forced swimming (from the experiment depicted in Figure 3 ). We did not find any statistically significant changes of monoamines or their metabolite contents between vehicle-or SR141716-treated CB1
À/À and CB1 þ / þ mice (Table 2 ). However, alterations of synaptic monoaminergic transmission could be masked by tissue homogenization and measurement of the total content of intra-and extracellular monoamines. To help clarifying this issue in detail, it will be necessary to apply high-resolution methods that are able to detect extracellular monoamine release, such as microdialysis, in the future.
Apart from the monoamine theory of depression, dysregulation of neurotrophic factors in the brain are also held responsible for the development of depression. 49 A downregulation of BDNF in the hippocampus, for example, is believed to correlate with depression-like behavior, and injections of BDNF into the hippocampus have been demonstrated to lead to decreased floating in the FST. 37 As we could recently demonstrate that endocannabinoid signaling via CB1 receptors regulates BDNF expression, 2, 43 we investigated BDNF mRNA expression in the hippocampus of CB1 À/À and CB1 þ / þ mice. In situ hybridization revealed a specific downregulation of BDNF mRNA in the CA3 region of the hippocampus of CB1 À/À mice (Figure 7 ), which might, thus, be related to the depression-like FST phenotype in CB1 À/À mice.
An upregulation of VGLUT1 mRNA expression has recently been proposed as a marker for antidepressant activity. 36 This finding appears particularly interesting in light of the compelling evidence that glutamatergic dysfunction can be related to psychiatric disorders (for review see Javitt 50 ). Taking recent evidence into account that CB1 receptors are, in addition to GABAergic terminals, as well prominently present on glutamatergic synapses 2, 3 where they colocalize with VGLUT1 and influence glutamatergic transmission, 3 it was reasonable to hypothesize a potential dysregulation of VGLUT1 expression in CB1 À/À mice. Nevertheless, in situ hybridization of VGLUT1 mRNA in the brain revealed no alterations in CB1 À/À mice ( Figure  6 ). However, this result rules out that the differences in BDNF mRNA levels simply relate to an age-dependent decline in the number of neurons in CB1 À/À mice. 24 In summary, we propose that impaired CB1 receptor signaling, which seems to compromise BDNF expression in the hippocampus, can lead to increased passive stresscoping behaviors in the FST and slightly altered behavioral responses to acute antidepressant treatment. Thus, our results generally support the findings from the human rimonabant phase-III trials reporting a slightly increased percentage of patients with anxiety and depressed mood as compared to placebo controls. [29] [30] [31] However, in order to help define a clear pro-or antidepressant effect of CB1 receptor blockade in rodents, it is certainly necessary to further evaluate these effects in the future in a number of additional depression-related animal paradigms, such as, for instance, the chronic mild stress, learned helplessness and tail suspension tests.
Materials and methods

Animals
Mice were kept under standard conditions with food and water ad libitum. They were housed in groups with a 12:12 h inverted light/dark schedule (lights off at 0900 hours). Animals were separated and single housed 2 weeks before experiments. C57BL/6N mice were purchased from Charles River (Germany). CB1 receptor-deficient mice (CB1 À/À ) and their wild-type littermates (CB1 þ / þ ) were maintained on a predominant C57BL/6N background (six backcrossings) and generated and genotyped as described. 8 The age of the animals during testing ranged between 3 and 6 months. Female mice were not controlled for the estrus cycle, because preliminary experiments failed to reveal any correlation between behavioral performance in the FST and estrus cycle phase as determined by vaginal smears at the experimental day (data not shown). Animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals of the local Government of Bavaria, Germany. Experiments were performed during the second half of the dark, active phase of the animals under red-light conditions.
Forced swim test
Each mouse was placed into a 5-l glass beaker (height 23.5 cm; diameter 16.5 cm) containing water up to a height of 15 cm at 25711C for 6 min. The water was changed between subjects. During each trial, floating (immobility) and struggling time was scored by pressing preset keys on a computer keyboard, using customized freeware software (EVENTLOG; Robert Hendersen 1986). The remaining time of the 6 min that the mice did not spend floating or struggling was assigned to swimming. Time spent swimming was not reported to avoid redundancy. The resulting two-channel ethogram was further processed by customized software (Winrat Vers. 2.31; Heinz Barthelmes, MPI Munich). A mouse was judged floating when it stopped any movements except those that were necessary to keep its head above water. Vigorous swimming movements involving all four limbs of the mouse with the front paws breaking the surface of the water, usually at the walls of the cylinder, were regarded as struggling. Although struggling is more prominent in rats and commonly scored only in the rat FST, we have found that struggling can also be precisely defined in mice and have found it worthwhile analyzing. As struggling in mice almost exclusively occurs during the first 1-2 min of the first exposure to the FST on day 1, it very likely refers to arousal of the animals upon first encounter with water exposure. We have previously found that, in addition to floating, also struggling can be specifically influenced by certain factors (for instance by certain antidepressants or corticotropin releasing hormone). Animals' behavior was analyzed on-line by trained observers who were blind to treatment and genotype. Animals were tested twice, on days 1 and 2, or three times, on days 1, 2 and 21.
Pharmacology
SR141716 (NIMH Chemical Synthesis and Drug Supply
Program, Bethesda, MA, USA) was dissolved in vehicle solution (one drop of Tween-80 in 3 ml of 2.5% dimethylsulfoxide in 0.9% saline) and injected at a dose of 10 mg/kg in a volume of 10 ml/kg body weight intraperitoneally (i.p.) 2 h before the FST on day 1, once again 10-12 h later, and 2 h before forced swimming on day 2. Desipramine hydrochloride (Sigma-Aldrich, Steinheim, Germany) and paroxetine hydrochloride (Dongyang Pharmaceutical Chemical Co. Ltd, Dongyang City, Zhejiang, China) were dissolved in vehicle solution (2% dimethylsulfoxide in saline) and injected at a dose of 20 mg/kg (an effective dose in male C57BL/6N mice as evaluated in preliminary experiments) in a volume of 10 ml/kg body weight i.p. 30 min before the FST on days 1 and 2 and once in between, 10-12 h after the first injection.
In situ hybridization Naive male CB1 þ / þ and CB1 À/À mice were killed by decapitation during the second half of the dark phase. Brains were quickly removed, frozen on dry ice and stored at À801C. Brains were mounted on Tissue Tek (Polysciences, Eppelheim, Germany), and 20 mm thick coronal sections were cut on a cryostat Microtome HM560 (Microm, Walldorf, Germany). Sections were mounted onto frozen SuperFrost/ Plus slides (Fisher Scientific, Schwerte, Germany), dried on a 351C warming plate and stored at À201C. In situ hybridizations for BDNF and VGLUT1 mRNA were performed as previously described. 2, 3 Densitometric analyses were performed on autoradiographic films using the NIH Image software (http://rsb.info.nih.gov/nih-image/Default.html).
Determination of MAO enzymatic activity Naive female CB1 þ / þ and CB1 À/À mice were killed by decapitation during the second half of the dark phase and the cortex, hippocampus and striatum were rapidly dissected, frozen and stored at À801C until assay. The enzymatic activity of MAO-A and MAO-B was measured according to a previous protocol. 51 Briefly, brain regions were homogenized in 20 volumes of ice-cold 20 mM Na-phosphate buffer containing 0.2% Triton-X 100 (w/w). For the assay of MAO-A and MAO-B, the homogenates were further diluted 1/12.5 and 1/25, respectively, with 20 mM phosphate buffer 0.2% Triton-X 100. Since the mouse brain contains both MAO isoforms, homogenate aliquots destined to MAO-A assay were pre-incubated with the selective MAO-B inhibitor L-deprenyl (10 mM), whereas those destined to the MAO-B assay were pre-incubated with the selective MAO-A inhibitor clorgyline (1 mM). 5-HT (100 mM) was used as a substrate for MAO-A assay, whereas phenylethylamine (20 mM) was used for MAO-B assay. Blanks were prepared by addition of both clorgyline and L-deprenyl to the homogenates. The progress of the enzymatic reaction was monitored fluorometrically (excitation 544 nm and emission 590 nm) at room temperature in a PolarStar Galaxy microplate reader (BMG Labtech, Aylesbury, UK). Data were expressed in nmol of substrate metabolized/h/mg protein.
Protein content was measured with the Pierce BCA protein assay reagent (Perbio Science, Bonn, Germany).
Determination of monoamine concentrations
Ten minutes after the beginning of the FST on day 2, subchronically vehicle and SR141716-treated female CB1 þ / þ and CB1 À/À animals were killed by decapitation and hippocampi freshly dissected on an ice-cold plate. Tissue samples were weighed and stored at À801C until further processing. Concentrations of the monoamines NA, DA, 5-HT as well as of their metabolites DOPAC, HVA and 5-HIAA were measured by high-performance liquid chromatography coupled with electrochemical detection. Brain tissues were homogenized on ice in 0.1 M ice-cold perchloric acid (Sigma-Aldrich, Steinheim, Germany) containing 50 nmol/l 3,4-dihydroxybenzylamine (Sigma-Aldrich, Steinheim, Germany) as internal standard. Samples were centrifuged at 16 000 g for 10 min and supernatants filtered through 0.45 mm Millipore type HV filters (Millipore, Schwalbach, Germany). Ten microliter of each sample were automatically injected into a liquid chromatographic system, which consisted of a Dionex P680 isocratic pump (Dionex, Idstein, Germany), a refrigerated (41C) Dionex ASI-100 microsampler (Dionex, Idstein, Germany) and an amperometric Decade detector (cell potential set at þ 0.85 V) equipped with a VT-03 flow cell (Antec, Leyden, The Netherlands). Chromatographic separation of catecholamines, 5-HT and metabolites was achieved on a Gemini C18 analytical column, 2 mm i.d. Â 25-cm length, with 5-m particle size (Phenomenex, Aschaffenburg, Germany). The mobile phase consisted of 0.1 M potassium phosphate buffer, 100 mg/l 1-octanesulfonic acid sodium salt, 50 mg/l ethylenediaminetetraacetic acid and methanol 4.5% (v/v), and was adjusted to pH 2.2 with H 3 PO 4 (all chemicals from SigmaAldrich, Steinheim, Germany). The flow cell and the analytical column were maintained at a temperature of 401C. The flow rate was 0.18 ml/min. The chromatograms were analyzed and integrated using a computerized data acquisition system equipped with Chromeleon chromatographic software (Dionex, Idstein, Germany). Compound identification and peak quantification were achieved by comparison with known standards. All samples were measured in duplicate and average values were expressed as pmol/mg of fresh weight of brain tissue.
Statistical analysis
For multiple comparisons data were analyzed using two-or three-way ANOVA for repeated measures where appropriate, followed by post hoc Newman-Keuls Multiple Comparison Test. For two-group comparisons unpaired Student's t-test was used. Differences were considered statistically significant if Po0.05. FST data (mean7s.e.m.) are presented either as the total behavioral performance shown during the entire 6-min observation period or as the behavioral performance shown during each of the six 1 min intervals of a single exposure.
